FA
NVNO

Fermata Advisors’s enVVeno Medical NVNO Stock Holding History

Fermata Advisors’s Portfolio NVNO Stock Details NVNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-935
Closed -$10.5K – 239
2025
Q4 		$10.5K Sell
935
-135
-13% -$2.62K ﹤0.01% 217
2025
Q3 		$33.9K Sell
1,070
-74
-6% -$7.56K 0.01% 211
2025
Q2 		$160K Buy
1,144
+18
+2% +$2.13K 0.04% 215
2025
Q1 		$104K Buy
1,126
+106
+10% +$11.8K 0.02% 280
2024
Q4 		$108K Buy
1,020
+156
+18% +$17.4K 0.02% 261
2024
Q3 		$102K Sell
864
-20
-2% -$3.67K 0.02% 241
2024
Q2 		$162K Buy
884
+221
+33% +$38.6K 0.04% 216
2024
Q1 		$126K Buy
663
+197
+42% +$35.4K 0.03% 205
2023
Q4 		$83.9K Buy
466
+127
+37% +$20.2K 0.02% 186
2023
Q3 		$63.9K Buy
+339
New +$56.5K 0.02% 159

Other funds holding NVNO

KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Fermata Advisors's NVNO Position: Q1 2026 in Review

Fermata Advisors sold out of enVVeno Medical (NVNO) in Q1 2026, closing a stake of 935 shares — an estimated $10.5K sold.

Fermata Advisors first reported a position in NVNO in Q3 2023 and held it in 10 quarters. The position peaked at $162K in Q2 2024. 17 funds tracked by Wall St. Rank hold NVNO as of Q1 2026.

  • Fermata Advisors reported no remaining enVVeno Medical position as of Q1 2026 after selling out during the quarter.
  • Fermata Advisors sold 935 enVVeno Medical shares in Q1 2026, an estimated $10.5K.
  • Fermata Advisors first reported a position in enVVeno Medical in Q3 2023 and held it in 10 quarters.
  • Fermata Advisors's enVVeno Medical position peaked at $162K in Q2 2024.
  • 17 funds tracked by Wall St. Rank held enVVeno Medical as of Q1 2026.

Based on Fermata Advisors's 13F filing for Q1 2026, filed 8 Apr 2026.